170399 ⎘
Assays involving biological materials from specific organisms or of a specific nature from animals; from humans Assays involving growth factors
Sub-classes:GDF-15 AS A DIAGNOSTIC MARKER TO PREDICT THE CLINICAL OUTCOME OF A TREATMENT WITH IMMUNE CHECKPOINT BLOCKERS
#2IN VITRO CELL-BASED POTENCY ASSAY
#3PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF NEUROLOGICAL DISEASES COMPRISING HIGHLY POTENT STEM CELLS EXPRESSING TIMP-1, MCP-1, GROa, AND IL-6, AND METHOD FOR SELECTING HIGHLY POTENT STEM CELLS
#4METHODS OF FORMING PATIENT-DERIVED 3D CELL CULTURES FOR TRACKING LIVE IMMUNE-TUMOR INTERACTIONS
#5MMP-14 OR TIMP POTENCY ASSAY FOR MESENCHYMAL STEM CELLS
#6BIOMARKERS
#7NEUTRALIZATION ANTIBODY ASSAY METHOD
#8TARGETING GDF15-GFRAL PATHWAY
#9IDENTIFICATION OF TDP-43 CRYPTIC EXON-ENCODED NEOEPITOPES AS FUNCTIONAL FLUID BIOMARKERS FOR ALZHEIMER'S DISEASE AND RELATED DEMENTIA
#10TREATING TUBEROUS SCLEROSIS COMPLEX-ASSOCIATED DISEASES
#11BIOMARKERS FOR CEREBRAL METABOLIC DISORDERS, AND DIAGNOSTIC METHODS USING THEREOF
#12METHOD FOR DETERMINING THE PROGNOSTIC SCORE IN PATIENTS WITH METASTATIC RENAL CARCINOMA
#13BLADDER CANCER BIOMARKERS AND METHODS OF USE
#14DIAGNOSTICHOME KIT TODETECTMIDKINE LEVELIN BLOOD
#15BLOOD BIOMARKERS IN LONG-COVID-19
#16SYSTEMS AND METHODS TO IDENTIFY AND TREAT SUBJECTS AT RISK FOR OBSTETRICAL COMPLICATIONS
#17MARKER FOR SELECTING HIGH-QUALITY STEM CELLS, AND METHOD FOR SELECTING HIGH-QUALITY STEM CELLS USING SAME
#18BIOMARKER PANEL FOR DIAGNOSIS OR PREDICTION OF BRAIN METASTASIS OF LUNG CANCER, AND USE THEREOF
#19COMPANION METHODS AND KITS FOR IL-2-BASED THERAPIES AND MESENCHYMAL STEM CELL-BASED THERAPIES
#20MEANS AND METHODS APPLYING sFlt-1/PIGF OR ENDOGLIN/PIGF RATIO TO RULE OUT ONSET OF PREECLAMPSIA WITHIN A CERTAIN TIME PERIOD
#21BIOMARKERS AND THEIR USE IN DIAGNOSING PARKINSON'S DISEASE, VITREORETINAL DISEASES, AND AGE-RELATED PATHOLOGIES
#22ANTIBODY MOLECULE AGAINST GROWTH AND DIFFERENTIATION FACTOR 15 AND USE THEREOF
#23VEGF MUTANTS AND MODULATION OF INTEGRIN-MEDIATED SIGNALING
#24PRODUCTS AND USES THEREOF FOR PREDICTING THE SENSITIVITY OF A SUBJECT TO CANCER IMMUNOTHERAPY INVOLVING AN ANTI-PD(L)1 AND AN ANTI-ANGIOGENIC AGENT, AND FOR SELECTING OPTIMIZED THERAPY
#25KIDNEY-ON-A-CHIP COMPRISING RENAL TUBULE CULTURE PART AND INTERSTITIUM CULTURE PART
#26PRODUCTS AND USES THEREOF FOR PREDICTING THE SENSITIVITY OF A SUBJECT TO CANCER IMMUNOTHERAPY AND FOR SELECTING OPTIMIZED THERAPY
#27BIOMARKERS FOR COLORECTAL CANCER
#28PROPHYLACTIC OR THERAPEUTIC AGENT FOR ACUTE RENAL FAILURE
#29GDF15 MARKER PANELS FOR EARLY DETECTION OF SEPSIS
#30Treatment of Cancers Lacking EGFR- Activating Mutations
#31VEGFA-BINDING MOLECULES
#32NOVEL LIPOCALIN MUTEINS SPECIFIC FOR CONNECTIVE TISSUE GROWTH FACTOR (CTGF)
#33NOVEL ANTI-HVEGFR2 ANTIBODIES
#34METHOD AND KIT FOR PREDICTING PREECLAMPSIA
#35Bioengineered and standardized Human Tissue Reference Controls for Validation of IHC, FISH or CISH Cancer Test Results
#36VEGFA-BINDING MOLECULES
#37Macrophage Stimulating 1 Receptor (MST1R) Variants And Uses Thereof
#38PD-ECGF as biomarker of cancer
#39TESTING COLON CANCER DRUGS FOR IMMUNOMODULATORY EFFECTS
#40METHOD FOR IDENTIFYING ANTI-CANCER AGENTS USING AN IN VITRO CELL CULTURE SYSTEM THAT MAINTAINS CANCER CELL STEMNESS
#41USES OF CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPIES IN COMBINATION WITH INHIBITORS OF INFLAMMATION-RELATED SOLUBLE FACTORS
#42GDF-15 AS A DIAGNOSTIC MARKER FOR MELANOMA
#43COMBINATION OF BIOMARKERS OF PRETERM DELIVERY
#44GDF3 AS BIOMARKER AND BIOTARGET IN POST-ISCHEMIC CARDIAC REMODELING
#45SIMULATED SYNOVIAL FLUIDS FOR MODELING DEGENERATIVE JOINT DISEASES AND SCREENING FOR THERAPEUTICS FOR SAME
#46Systems and methods to identify and treat subjects at risk for obstetrical complications
#47METHODS FOR QUANTIFYING POTENCY OF REGENERATIVE IMMUNOTHERAPIES
#48ADRENOMEDULLIN (ADM) FOR DIAGNOSIS AND/OR PREDICTION OF DEMENTIA AND ANTI-ANDRENOMEDULLIN BINDER FOR USE IN THERAPY OR PREVENTION OF DEMENTIA
#49PROBIOTIC FOR THE TREATMENT OF INFERTILITY AND RECURRENT PREGNANCY LOSS
#50SMALL EXTRACELLULAR VESICLE-ASSOCIATED VEGF AS A PREDICTOR FOR THERAPEUTIC RESPONSES
#51Biomarkers and Methods for Measuring and Monitoring Inflammatory Disease Activity
#52METHODS AND DEVICES FOR THE PRODUCTION AND DELIVERY OF BENEFICIAL FACTORS FROM STEM CELLS
#53BIOMARKERS FOR ASSESSING EXPLANT ORGAN VIABILITY
#54METHOD FOR DIAGNOSING AND MONITORING INFLAMMATORY DISEASE PROGRESSION
#55METHODS AND COMPOSITIONS FOR DETECTION AND TREATMENT OF LUNG CANCER
#56Modular point-of-care devices, systems, and uses thereof
#57GDF-15 AS A DIAGNOSTIC MARKER TO PREDICT THE CLINICAL OUTCOME OF A TREATMENT WITH IMMUNE CHECKPOINT BLOCKERS
#58Targeted apheresis to treat preeclampsia
#59MARKER FOR STATIN TREATMENT STRATIFICATION IN HEART FAILURE
#60BIOMARKERS FOR DIAGNOSIS OF OCULAR DISEASES AND THE METHOD THEREOF
#61DYNAMIC OF SFLT-1 OR ENDOGLiN/PIGF RATIO AS AN INDICATOR FOR IMMINENT PREECLAMPSIA AND/OR HELLP SYNDROME
#62METHODS FOR BINDING SITE IDENTIFICATION USING HYDROGEN EXCHANGE MASS SPECTROMETRY
#63Use of GDF-15 in the Diagnosis and Treatment of Frailty and Conditions Associated with Altered Physiological Reserve, Physical Fitness and Exercise Capacity
#64METHODS FOR ASSESSING THE PURITY OF A MESENCHYMAL STEM CELLS PREPARATION
#65ADRENOMEDULLIN (ADM) FOR DIAGNOSIS AND/OR PREDICTION OF DEMENTIA AND ANTI-ADRENOMEDULLIN BINDER FOR USE IN THERAPY OR PREVENTION OF DEMENTIA
#66METHOD FOR PREDICTING THE OUTCOME OF A TREATMENT WITH AFLIBERCEPT OF A PATIENT SUSPECTED TO SUFFER FROM A CANCER BY MEASURING THE LEVEL OF A PLASMA BIOMARKER
#67RAPID POLYMERIZATION OF POLYPHENOLS
#68COMPOSITIONS FOR THE TREATMENT OF SARCOPENIA OR DISUSE ATROPHY
#69BIOMARKERS FOR UROTHELIAL CARCINOMA AND APPLICATIONS THEREOF
#70METHODS AND DEVICES FOR DETECTING DIABETIC NEPHROPATHY AND ASSOCIATED DISORDERS
#71CES-2 (CARBOXYLESTERASE-2) FOR THE ASSESSMENT OF AFIB RELATED STROKE
#72METHOD OF ASSESSING WOUND HEALING POTENCY OF A MESENCHYMAL STEM POPULATION AND RELATED METHODS OF SELECTING MESENCHYMAL STEM CELLS AND IDENTIFYING TISSUE AS STARTING MATERIAL FOR PRODUCING A MESENCHYMAL STEM CELL POPULATION
#73Method for identifying anti-cancer agents using an in vitro cell culture system that maintains cancer cell stemness
#74Methods and compositions for diagnosis and prognosis of renal injury and renal failure
#75Macrophage stimulating 1 receptor (MST1R) variants and uses thereof
#76BIOMARKER COMBINATION FOR IDENTIFICATION OF "AT-RISK" SUBJECTS FOR AKI
#77Biomarkers and Methods for Measuring and Monitoring Inflammatory Disease Activity
#78Reagents and Methods for Breast Cancer Detection
#79SPECIFIC BIOMARKER SET FOR NON-INVASIVE DIAGNOSIS OF LIVER CANCER
#80GDF-15 AS A DIAGNOSTIC MARKER FOR MELANOMA
#81BIOMARKERS FOR RISK PREDICTION OF MORTALITY
#82Molecularly imprinted polymer sensors for neurotrophic factors
#83COMPOSITION FOR PREDICTING OR DIAGNOSING LIVER DISEASE, AND LIVER DISEASE PREDICTION OR DIAGNOSIS METHOD USING SAME
#84TARGETING GDF6 AND BMP SIGNALING FOR ANTI-MELANOMA THERAPY
#85Method for prediction of response to cardiovascular regeneration based on detecting the amount of biomarkers
#86Image selection suggestions
#87Methods for cancer detection with quantum dots
#88Anti-angiogenic therapy of metastatic colorectal cancer
#89FATTY ACID BINDING PROTEIN 3 FOR THE ASSESSMENT OF ATRIAL FIBRILLATION (AF)
#90Assessing susceptibility to cardiac intervention, susceptibility to therapy for heart failure, risk of mortality or further cardiovascular events, and risk of subsequent pulmonary embolism in relevant patients based on determinations of GDF-15, natriuretic peptide, cardiac troponin or combinations thereof
#91Treatment for age-related macular degeneration (AMD) and pathogenic ocular neovascularization
#92Systems and methods to identify and treat subjects at risk for obstetrical complications
#93METHOD FOR MEASUREMENT AND CONTROL OF INTRACULAR VEGF CONCENTRATION
#94Methods for treating sarcopenia and muscle injury
#95PROGNOSIS OF ADVERSE OUTCOMES BY DETERMINATION OF MIDKINE LEVELS AFTER CARDIOVASCULAR STRESS
#96Anti-IGF antibodies
#97PREDICTIVE BIOMARKERS OF CLINICAL RESPONSE TO ANTI-LPS IMMUNOGLOBULIN TREATMENT
#98METHOD OF TREATMENT AND PROGNOSIS
#99METHODS FOR SELECTING IMPROVED STEM CELL FOR TREATING INTRAVENTRICULAR HEMORRHAGE OF PREMATURE INFANTS
#100Marker for statin treatment stratification in heart failure
#101CYR61 AS A BIOMARKER FOR DIAGNOSIS AND PROGNOSIS OF CANCERS OF EPITHELIAL ORIGIN
#102Method of treating asthma using an IL-13 antibody
#103PREECLAMPSIA BIOMARKERS AND RELATED SYSTEMS AND METHODS
#104GDF-15 AS A DIAGNOSTIC MARKER FOR MELANOMA
#105Platelet biomarkers and diagnostic methods for vascular diseases
#106Soluble MANF in pancreatic beta-cell disorders
#107GDF-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers
#108Screening for anti-cancer compounds using netrin-1 activity
#109Reagents and Methods for Breast Cancer Detection
#110Diagnosis of cancer by detecting auto-antibodies against vascular endothelial growth factor (VEGF)
#111Prostate cancer markers and uses thereof
#112METHOD AND KIT FOR DIAGNOSING EPITHELIAL-TO-MESENCHYMAL TRANSITION (EMT) OF THE PERITONEUM
#113Modular point-of-care devices, systems, and uses thereof
#114METHOD FOR PARALLEL QUANTIFICATION OF PROTEIN VARIANT
#115Modular point-of-care devices, systems, and uses thereof
#116Method for identifying anti-cancer agents using an in vitro cell culture system that maintains cancer cell stemness
#117Method for decreasing depression-like behavior with connective tissue growth factor (CTGF) inhibitor
#118Predictive biomarkers
#119Methods and devices for rapid assessment of severity of injury
#120Methods and devices for the production and delivery of beneficial factors from adipose-derived stem cells
#121Immune profiling and minimal residue disease following stem cell transplantation in multiple myeloma
#122Compositions and methods for diagnosing breast cancer
#123Treatment with an IL-2 based therapy
#124Methods for assessing the purity of a mesenchymal stem cells preparation
#125METHOD FOR PREDICTING THE OUTCOME OF A TREATMENT WITH AFLIBERCEPT OF A PATIENT SUSPECTED TO SUFFER FROM A CANCER BY MEASURING THE LEVEL OF A PLASMA BIOMARKER
#126Predictive biomarkers of clinical response to anti-LPS immunoglobulin treatment
#127Nanorobot
#128HOMOGENOUS AND HETEROGENEOUS ASSAYS AND SYSTEMS FOR DETERMINATION OF OCULAR BIOMARKERS
#129Method for diagnosing and monitoring inflammatory disease progression
#130Biomarkers in Cancer, Methods, and Systems Related Thereto
#131PD-ECGF as biomarker of cancer
#132Nucleic acid compounds for binding growth differentiation factor 8
#133Methods and Devices for Detecting Diabetic Nephropathy and Associated Disorders
#134Compositions and methods for the prevention and treatment of mast cell-induced vascular leakage
#135Predictive and prognostic biomarkers related to anti-angiogenic therapy of metastatic colorectal cancer
#136ELISA FOR VEGF
#137Diagnosis of cancer by detecting auto-antibodies against vascular endothelial growth factor (VEGF)
#138Methods and compositions for diagnosis and prognosis of renal injury and renal failure
#139Systems and methods to identify and treat subjects at risk for obstetrical complications
#140Midkine antibody
#141Capped and conjugated quantum dots
#142METHODS OF DIAGNOSING AND PROGNOSING COLONIC POLYPS
#143Methods of using pigment epithelium derived factor (PEDF) for the treatment and prevention of agent-induced gonadal or uterine toxicity
#144Diagnosis of cancer by detecting auto-antibodies against vascular endothelial growth factor receptor (VEGFR)
#145Biomarkers and Methods for Measuring and Monitoring Inflammatory Disease Activity
#146Specific biomarker set for non-invasive diagnosis of liver cancer
#147Assay to measure midkine or pleiotrophin level for diagnosing a growth
#148Adult stem cells derived from human skin dermis
#149INDIVIDUALIZED TREATMENT OF EYE DISEASE
#150METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE
#151Biomarkers associated with schizophrenia
#152Modular point-of-care devices, systems, and uses thereof
#153Modular point-of-care devices, systems, and uses thereof
#154GDF15 AS BIOMARKER FOR DIAGNOSING MITOCHONDRIAL DISEASES
#155ARMET AS A MARKER FOR CANCER
#156QUANTITAQUANTITATIVE DIAGNOSTIC METHODS USING MULTIPLE PARAMETERS
#157System and Method for Determining Risk of Pre-Eclampsia Based on Biochemical Marker Analysis
#158Predicting therapeutic response in Parkinson's disease
#159TRANSGENIC ANIMAL MODEL OF MOOD DISORDERS
#160Olfactomedin-4, neudesin and desmoplakin as biomarkers of breast cancer
#161Method for diagnosing and monitoring inflammatory disease progression
#162TARGETING GDF6 AND BMP SIGNALING FOR ANTI-MELANOMA THERAPY
#163Methods of treating metabolic disorders
#164METHODS FOR DIAGNOSING CANCER AND DETERMINING THE OVERALL SURVIVAL AND DISEASE-FREE SURVIVAL OF CANCER PATIENTS
#165Modular point-of-care devices, systems, and uses thereof
#166Modular point-of-care devices, systems, and uses thereof
#167Modular point-of-care devices, systems, and uses thereof
#168Methods and Devices for Detecting Kidney Damage
#169Gene and protein expression properties of adherent stromal cells cultured in 3D
#170Marker for statin treatment stratification in heart failure
#171Dual-targeting protein binding specifically to DLL4 and VEGF and use thereof
#172Modular point-of-care devices, systems, and uses thereof
#173Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
#174Methods of using VEGF-C biomarkers for age-related macular degeneration (AMD) diagnosis
#175Surface plasmon resonance based sensing devices and methods for real-time analysis of analyte secretion from living cells
#176Methods and compositions for diagnosis and prognosis of renal injury and renal failure
#177Elisa for VEGF
#178Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
#179QUANTITATIVE DIAGNOSTIC METHODS USING MULTIPLE PARAMETERS
#180Modular point-of-care devices, systems, and uses thereof
#181Biomarkers and methods for measuring and monitoring inflammatory disease activity
#182Modular point-of-care devices, systems, and uses thereof
#183Vascular endothelial growth factor-binding aptamers
#184Modular point-of-care devices, systems, and uses thereof
#185Means and methods applying sFlt-1/PlGF or endoglin/PlGF ratio to rule out onset of preeclampsia within a certain time period
#186BIOMARKERS IN CANCER, METHODS, AND SYSTEMS RELATED THERETO
#187Methods and devices for rapid assessment of severity of injury
#188ACUTE KIDNEY INJURY
#189Assay to measure midkine or pleiotrophin level for diagnosing a growth
#190Methods and Devices for Detecting Diabetic Nephropathy and Associated Disorders
#191METHODS OF PROGNOSTICATING AND TREATING CANCER
#192Reagents for reducing leukocyte interference in immunoassays
#193Diagnosis and risk stratification of bladder cancer
#194COMPOSITIONS FOR MODULATING INVASION ABILITY OF A TUMOR AND METHODS THEREOF
#195PRE-SELECTION OF SUBJECTS FOR THERAPEUTIC TREATMENT WITH AN HSP90 INHIBITOR BASED ON HYPOXIC STATUS
#196Method for detection of IGFBP-4 fragments
#197Modulation sAPP, sAAPα and BDNF levels in individuals diagnosed with FXS and ASD
#198Soluble MANF in pancreatic β-cell disorders
#199Modular point-of-care devices, systems, and uses thereof
#200METHOD AND KIT FOR DETECTING THE EARLY ONSET OF RENAL TUBULAR CELL INJURY
#201Susceptibility to and stratification for monoaminergic antidepressants
#202DETERMINATION OF EFFICIENT TIME(S) FOR CHEMOTHERAPY DELIVERY
#203Methods and Compositions for Treating or Diagnosing Melanoma
#204Host Biomarkers for Dengue Fever (DF) and Methods Thereof
#205PEPTIDE AND ANTIBODY LIBRARIES AND USES THEREOF
#206Method for treating muscle wasting syndrome using antagonist antibodies against GDF-8
#207Methods and devices for tuberculosis diagnosis using biomarker profiles
#208METHOD AND PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT AND DIAGNOTIC OF ANEMIA OF INFLAMMATION
#209Anti-VEGF antibodies
#210Methods and kits for diagnosing osteoarthritis and predicting progression
#211Anti-HER2 and anti-IGF-IR BI-specific antibodies and uses thereof
#212Methods and Devices for Rapid Assessment of Severity of Injury
#213Transgenic animal model of mood disorders
#214Compositions and methods for the prevention and treatment of mast cell-induced vascular leakage
#215Compositions and Methods of Detecting and Treating Neural Tube Defects
#216Anti-IGF antibodies
#217BIOMARKERS
#218Determination of sFlt-1:angiogenic factor complex
#219MACC1 AS A PROGNOSTIC BIOMARKER FOR HEPATOBILIARY TUMORS
#220Predictive biomarker of survival in the treatment of renal cell carcinoma
#221Single Molecule Assays
#222BLOOD PLASMA BIOMARKERS FOR BEVACIZUMAB COMBINATION THERAPIES FOR TREATMENT OF BREAST CANCER
#223VEGF-specific capture agents, compositions, and methods of using and making
#224COMPOSITIONS FOR MODULATING INVASION ABILITY OF A TUMOR AND METHODS THEREOF
#225Diagnosis and treatments relating to TH2 inhibition
#226Diagnosis and treatments relating to TH2 inhibition
#227Biological markers for identifying patients for treatment with VEGF antagonists
#228Agonistic antibodies to TrkC receptors and uses thereof
#229Methods for the identification and treatment of patients sensitive to anti IGF-1R inhibition therapy
#230Gynogenetic or androgenetic production of pluripotent cells and cell lines, and use thereof to produce differentiated cells and tissues
#231Growth factor isoform
#232METHOD AND KIT FOR DETECTING THE EARLY ONSET OF RENAL TUBULAR CELL INJURY
#233Prediction and recognition of acute kidney injury after surgery
#234Methods and materials for the diagnosis of prostate cancers
#235ELISA for VEGF
#236METHODS AND COMPOSITIONS FOR DIAGNOSTIC USE IN CANCER PATIENTS
#237METHODS OF DIAGNOSING AND PROGNOSING COLONIC POLYPS
#238Methods for the Diagnosis, Prognosis and Monitoring of Cancer Therapy Using BP1
#239Quantitative diagnostic methods using multiple parameters
#240NEUROTROPHINS AND USES THEREOF
#241Methods Of Determining Skeletal Maturity
#242NOVEL NETRIN DERIVATIVES AND USES THEREOF
#243Diagnostic kit for IGFBP-4 proteolytic fragments in a patient sample
#244Methods for inhibiting peritoneal dissemination of cancer cells
#245MARKER PANEL FOR LEFT VENTRICULAR HYPERTROPHY
#246DIAGNOSIS AND TREATMENTS RELATING TO TH2 INHIBITION
#247Modular point-of-care devices, systems, and uses thereof
#248Methods for determining maternal health risks
#249MYOSTATIN BINDING AGENTS
#250Methods and kits for diagnosing osteoarthritis and predicting progression
#251METHOD AND KIT FOR DETECTING THE EARLY ONSET OF RENAL TUBULAR CELL INJURY
#252Polynucleotides encoding antagonist antibodies against GDF-8
#253Method for treating muscular dystrophy using antagonist antibodies against GDF-8
#254METHODS FOR TREATMENT OF DEGENERATIVE DISEASE ASSOCIATED WITH APOPTOSIS
#255Methods and compositions for diagnosis and prognosis of renal injury and renal failure
#256BIOMARKERS
#257Gynogenetic or androgenetic production of pluripotent cells and cell lines, and use thereof to produce differentiated cells and tissues
#258Reagents for reducing leukocyte interference in immunoassays
#259CAPTURING AND DELIVERING MOLECULES IN A MAMMAL
#260METHOD FOR ASSESSMENT OF SEVERITY OF LIVER CIRRHOSIS
#261Secretory Granules and Granulogenic Factors as a Target for Cancer Treatment
#262METHODS TO TREAT OR PREVENT A SKIN CONDITION USING A NELL1 PEPTIDE
#263METHODS FOR DIAGNOSING CANCER AND DETERMINING THE OVERALL SURVIVAL AND DISEASE-FREE SURVIVAL OF CANCER PATIENTS
#264ARMET as a marker for cancer
#265CYR61 AS A BIOMARKER FOR DIAGNOSIS AND PROGNOSIS OF CANCERS OF EPITHELIAL ORIGIN
#266Methods to identify responsive patients
#267Methods and Devices for Detecting Kidney Transplant Rejection
#268CARBOLINE DERIVATIVES USEFUL IN THE INHIBITION OF ANGIOGENESIS
#269Immunogenic Peptides Derived from the Midkine Protein, as an Anticancer Vaccine
#270Anti-VEGF antibodies
#271Biomarkers and methods for measuring and monitoring inflammatory disease activity
#272RATIONAL DESIGN OF REGENERATIVE MEDICINE PRODUCTS
#273Fluorescent pyrene compounds
#274Methods for treatment or prevention of diseases associated with functional disorder of regulatory T cells
#275Devices for Detecting Renal Disorders
#276Methods and Devices for Detecting Kidney Damage
#277Methods and Devices for Detecting Diabetic Nephropathy and Associated Disorders
#278Computer Methods and Devices for Detecting Kidney Damage
#279Assessing susceptibility to cardiac intervention, susceptibility to therapy for heart failure, risk of mortality or further cardiovascular events, and risk of subsequent pulmonary embolism in relevant patients based on determinations of GDF-15, natriuretic peptide, cardiac troponin or combinations thereof
#280Methods and devices for detecting obstructive uropathy and associated disorders
#281Methods and Devices for Detecting Glomerulonephritis and Associated Disorders
#282METHOD FOR RISK REDUCTION IN GLYCEMIC CONTROL
#283Predicting renal failure in diabetes patients based on placental growth factor and soluble FLT-1
#284Pharmaceutical composition for inhibiting peritoneal dissemination
#285Method of increasing muscle mass by administering a myostatin binding agent
#286Growth factor isoform
#287Netrin-1 compositions and methods of use thereof
#288Method and apparatus for detecting and regulating vascular endothelial growth factor (VEGF) by forming a homeostatic loop employing a half-antibody biosensor
#289Method for assessing risk of heart failure
#290Anti-VEGF antibodies
#291SYNERGISTIC TREATMENT OF CELLS THAT EXPRESS EPHA2 AND ERBB2
#292METHOD AND KIT FOR DETECTING THE EARLY ONSET OF RENAL TUBULAR CELL INJURY
#293METHOD AND KIT FOR DETECTING THE EARLY ONSET OF RENAL TUBULAR CELL INJURY
#294Methods for stimulating nervous system regeneration and repair by regulating arginase I and polyamine synthesis
#295METHODS AND COMPOSITIONS FOR DIAGNOSTIC USE IN CANCER PATIENTS
#296Netrin-1 as a biomarker of injury and disease
#297Carboline derivatives useful in the inhibition of angiogenesis
#298Use of pleitrophin for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome
#299Anti-IGF antibodies
#300SINGLE MOLECULE ASSAYS